French diagnostics company bioMérieux (Euronext Paris:BIM) announced on Tuesday that it has received US Food and Drug Administration (FDA) 510(k) clearance and European IVDR CE marking for VITEK PRO, its new automated microbial identification (ID) and antimicrobial susceptibility testing (AST) platform.
The system is designed to support clinical laboratories in diagnosing infectious diseases and strengthening antimicrobial stewardship efforts.
Building on more than 35 years of ID/AST expertise, VITEK PRO combines automated workflows, digital capabilities and a broad antimicrobial testing menu. The platform enables laboratories to identify infection-causing microorganisms and determine their antimicrobial susceptibility, supporting timely clinical decisions and appropriate antibiotic selection.
Designed for medium- and high-volume laboratories, the system features scalable capacity to accommodate evolving testing requirements while improving operational efficiency and maintaining diagnostic reliability, bioMérieux said.
bioMérieux plans to begin commercial launches in selected markets, including the United States and parts of Europe, in the first quarter of 2027. Wider international availability is expected in the second quarter of 2027, as VITEK PRO progressively replaces the company's VITEK 2 and VITEK XL systems.
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Breakthrough T1D and Walgreens Foundation join forces to support the type 1 diabetes community
PAI Pharma acquires Nexus Pharmaceuticals
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
Guardant Health expands liquid biopsy test with AI-powered epigenomic applications
Nuvation Bio to present at Jefferies Global Healthcare Conference in London
AstraZeneca acquires biotechnology company Omniose to strengthen vaccine capabilities
Valneva reports 94% antibody persistence five years after single-dose chikungunya vaccination
bioMérieux secures FDA clearance and IVDR CE marking for VITEK PRO diagnostic platform
Energenesis Biomedical presents ENERGI-based approach to space anaemia at TASTI 2026
Janux reports positive Phase 1 data for JANX011, plans autoimmune trials in 2027
Illumina expands MRD research portfolio with ultrasensitive sequencing technology